TapImmune to Participate in Two Upcoming Investor Conferences

JACKSONVILLE, Florida, February 6, 2018 / TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang, will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.  He will also attend the 11th Annual European Life Sciences CEO Forum & Exhibition, held February 26-27, 2018, in Zurich, Switzerland.

 TapImmune Presentation Details:

Event: 2018 BIO CEO & Investor Conference

Date: Monday, February 12, 2018

Time: 2:30 PM (Eastern Time)

Location: New York Marriott Marquis, Odets Room

 An audio webcast will be accessible via the News and Events section of the TapImmune website: https://www.markertherapeutics.com/events. An archive of the audio will remain available for 90 days following the presentation.[/vc_column_text][vc_empty_space height=”8px”][vc_column_text][pr-disclaimer]